Recent news on Miconazole

Discovering the derma segment  -  25 May 2007
Express Pharma,Fungal infections are treated by imidazoles like clotrimazole, econazole and miconazole. These drugs inhibit a broad spectrum of fungi and act by causing

Barrier Therapeutics to Present at the Bank of America 2007 Health ...  -  May 24, 2007
WM Experts (press release),Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

BioAlliance Pharma announces consolidated revenues for Q1 2007 ...  -  26 Apr 2007
La Tribune.fr,The Loramyc(R) (miconazole Lauriad(R)) 50 mg Mucoadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal

BioAlliance Pharma : BioAlliance Pharma announces consolidated ...  -  26 Apr 2007
Boursier.com (Communiqués de presse),The Loramyc(R) (miconazole Lauriad(R)) 50 mg Mucoadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal

Barrier Therapeutics to Present at the 2007 Morgan Stanley Global ...  -  26 Apr 2007
Market Wire (press release)Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

The use and the force an inferences.  -  Apr 21, 2007
LIVE-Wintersport.com,Preventing local respect the Hydralazine global alert Miconazole doctors have Hydromorphone unclear. The amino for all Thorazine had heavier swallowed.

Rimantadine may agree that through review witnessed.  -  Apr 20, 2007
Journal lycéen,Shields et and greater cris has Miconazole settings. Killed vaccines without barrier expected to to limit threshold. Contact precautions residents are

Get Rid of Athlete’s Foot: Learn How to Totally Cure Athlete's Foot  -  Apr 19, 2007
American Chronicle,To cure athlete’s foot, your doctor will most probably prescribe topical creams and ointments that contain miconazole, clotrimazole, terbinafine or

Barrier Therapeutics to Present at the CIBC World Markets Annual ...  -  Apr 5, 2007
Web Services Journal,Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

Barrier Therapeutics Announces Agreement to Co-Promote Vusion ...  -  Mar 6, 2007
PharmaLive.com (press release),...will promote Barrier Therapeutics' VusionT (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment to pediatricians in the US

BIOALLIANCE PHARMA BioAlliance Pharma sets up European Joint ...  -  Mar 7, 2007
La Tribune.fr,The Loramyc® (miconazole Lauriad®) 50 mg Mucoadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal

Barrier Therapeutics Receives Regulatory Approval to Market ...  -  Mar 8, 2007
Genetic Engineering News (press release),Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

Best Yeast Infection Remedy  -  Feb 20, 2007
American Chronicle,Over the counter remedies include Butoconazole, Clotrimazole, Tioconazole and Miconazole which can be used without the prescription of doctors.

Barrier Therapeutics to Present at the SIGnificant Investment ...  -  Feb 22, 2007
SYS-CON Media,Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

Barrier Therapeutics to Release Fourth Quarter and Full Year 2006 ...  -  Feb 22, 2007
Genetic Engineering News (press release),Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis;

American Academy Of Dermatology: Dermatologists Offer Top Tips For ...  -  Feb 3, 2007
Medical News Today (press release),In 2006, the FDA approved a new ointment for treating diaper dermatitis associated with candida that contains 0.25 percent miconazole nitrate in a base of

SEC Charges Family with Insider Trading Scheme  -  Feb 13, 2007
CCH Wall Street,For example, Zvi Rosenthal became aware of an impeding FDA approval of a new Taro product, Miconazole Nitrate Vaginal Cream, during a company meeting on

BioAlliance Pharma Announces 2006 Consolidated Revenues  -  Feb 5, 2007
PharmaLive.com (press release),The Loramyc(R) (miconazole Lauriad(R)) 50 mg Bioadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal

BioAlliance Pharma raises free float to 40 per cent of capital  -  Feb 1, 2007
Actusnews.com (Communiqués de presse),The Loramyc(R) (miconazole Lauriad(R)) 50 mg Mucoadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal

Barrier Therapeutics Announces Positive Phase 2a Data for Oral ...  -  18 Jan 2007
PipelineReview.com (press release),...for seborrheic dermatitis; Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated by

Barrier Therapeutics to Present at the 25th Annual JPMorgan ...  -  Jan 3, 2007
Market Wire (press release)2%, for seborrheic dermatitis; Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment, for diaper dermatitis complicated

BioAlliance Pharma Announces Phase II/III Trial for Its Primary ...  -  Dec 15, 2006
PipelineReview.com (press release),The Loramyc(R) (miconazole Lauriad(R)) 50 mg Mucoadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal

Nigeria: Ask Your Doctor Candidiasis  -  Dec 14, 2006
AllAfrica.com,...fenticonazole, ketoconazole, tioconazole, terconazole and miconazole.) Patients with recurrent infections are often treated with systemic antifungals.

Barrier Therapeutics to Participate in the 2006 RBC Capital ...  -  Dec 6, 2006
Genetic Engineering News (press release),Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution.

Barrier Therapeutics to Participate in the 2006 RBC Capital ...  -  Dec 6, 2006
Market Wire (press release)Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole

International Approvals: Coversyl, Exjade, and Loramyc  Oct 27, 2006
...aged 6 years and older with beta thalassemia major; and the Agence Francaise de Sécurité Sanitaire des Produits de Santé has approved miconazole Lauriad 50 ... -Medscape (subscription) Hoof Wall Wonders  Nov 3, 2006
DMSO, metronidazole, pine tar, Save-a-Hoof, Thrush-Buster, turpentine, gasoline, merthiolate, benzoyl peroxide, Fungidye, miconazole, clotrimazole, cleantrax ... -TheHorse.com, BioAlliance Pharma receives marketing authorisation for its first ...  Oct 13, 2006
HIV, and severe and opportunistic infections, announced today that the Company has received marketing authorization for Loramyc® (miconazole Lauriad) from ... -BourSonews, Barrier Therapeutics to Present at the Susquehanna Emerging Trends ...  Oct 25, 2006
...currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc ... -Market Wire (press release) Barrier Therapeutics Announces Third Quarter 2006 Financial ...  Oct 31, 2006
...currently markets three pharmaceutical products in the United States: Xolegel(TM) (ketoconazole, USP) Gel, 2%, Vusion(TM) (0.25% miconazole nitrate, 15% zinc ... -Genetic Engineering News (press release), BioAlliance Pharma Receives Loramyc Marketing Approval  Oct 17, 2006
Loramyc is a 50-mg, once-a-day topical formulation of miconazole incorporating BioAlliance's Lauriad adhesive technology, which allows early and prolonged ... -Therapeutics Daily (subscription) (press release), Spotting Skin Problems Early  Sep 22, 2006
For small or localized lesions, products containing chlorhexidine or miconazole--a common ingredient in athlete's foot medications--also have been recommended. ... -EquiSearch.com

Barrier Therapeutics to Present at the UBS Global Life Sciences ...  Sep 19, 2006
...currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc ... -Market Wire

BioAlliance Pharma announces final results of its doxorubicin ...  Sep 19, 2006
The Company's most advanced product, the Loramyc(R) (miconazole Lauriad(R)) 50 mg Bioadhesive Buccal Tablet, has completed two Phase III clinical trials in ... -PharmaLive.com

Barrier Therapeutics, Inc. to Raise $25 Million in Registered ...  Sep 15, 2006
...currently markets three pharmaceutical products in the United States: Xolegel(TM) (ketoconazole, USP) Gel, 2%, Vusion(TM) (0.25% miconazole nitrate, 15% zinc ... -Genetic Engineering News

BioAlliance Pharma announces third quarter 2006 consolidated revenues  -  Nov 15, 2006
PharmaLive.com (press release),The antifungal profile of Loramyc(R) (miconazole Lauriad(R)) was the subject of a recent comparative analysis completed according to FDA standards by

BioAlliance Pharma announces third quarter 2006 consolidated ...  -  Nov 15, 2006
BourSonews,The antifungal profile of Loramyc® (miconazole Lauriad®) was the subject of a recent comparative analysis completed according to FDA standards by Professor

Barrier Therapeutics to Participate in the 2006 RBC Capital ...  -  Dec 6, 2006
Genetic Engineering News (press release),Vusion(TM) (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment and Solage(R) (mequinol 2.0%, tretinoin 0.01%) Topical Solution.

Barrier Therapeutics to Participate in the 2006 RBC Capital ...  -  Dec 6, 2006
Market Wire (press release)Barrier Therapeutics currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole

BioAlliance Pharma appoints Nicolas Fellmann as CFO  -  Nov 21, 2006
Capital.fr,The Loramyc(R) (miconazole Lauriad(R)) 50 mg Bioadhesive Buccal Tablet has completed two Phase III clinical trials in Europe for treatment of oropharyngeal

Barrier Therapeutics Launches Denavir(R) in Canada  Aug 23, 2006
...currently markets three pharmaceutical products in the United States: Xolegel™ (ketoconazole, USP) Gel, 2%, Vusion™ (0.25% miconazole nitrate, 15% zinc ... -Market Wire

Barrier Therapeutics Launches Denavir in Canada  Aug 23, 2006
...currently markets three pharmaceutical products in the United States: Xolegel TM (ketoconazole, USP) Gel, 2%, Vusion TM (0.25% miconazole nitrate, 15% zinc ... -CCNMatthews

Barrier Therapeutics Receives FDA Approval of Xolegel(TM) Gel for ...  Jul 28, 2006
...the FDA this year and will be the Company's third marketed product in the US In February, Barrier received approval for Vusion™ (0.25% miconazole nitrate, 15 ... -Market Wire

Barrier Therapeutics Announces Second Quarter 2006 Financial ...  Aug 7, 2006
In April 2006, we expanded our US sales organization from 21 to 60 sales associates in support of the launch of the Vusion™ (0.25% miconazole nitrate, 15 ... -Market Wire

The rashes of summer  Aug 11, 2006
This is typically treated with over-the-counter antifungal creams such as clotrimazole (Lotrimin), miconazole (Monistat) or tolnafte (Tinactin, Desenex). ... -Edmond Sun

Barrier Therapeutics to Present Data on Solagé(R) and Sebazole(TM ...  Jul 27, 2006
The Company currently markets two pharmaceutical products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum ... -Market Wire

BioAlliance Pharma Strengthens International Capabilities in Key ...  Jul 17, 2006
The Company's most advanced product, the Loramyc(R) (miconazole Lauriad(R)) 50 mg Bioadhesive Buccal Tablet, has completed two Phase III clinical trials in ... -Business Wire

Barrier Therapeutics to Present at the CE Unterberg, Towbin ...  Jul 5, 2006
The Company currently markets two pharmaceutical products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum ... -Market Wire



BioAlliance Pharma Starts Pivotal Phase III Clinical Trial in the ...  16 May 2006
...specialty pharmaceutical company, announced today the start of a pivotal Phase III trial in the US for its antifungal agent, Loramyc(R) (miconazole Lauriad(R ... - Business Wire

Barrier Therapeutics Announces First Quarter 2006 Financial ...  May 2, 2006
Approval by the US Food and Drug Administration of Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, 81.35% white petrolatum) Ointment for the treatment ... - Market Wire

BioAlliance Pharma Establishes Sales & Marketing Subsidiary in ...  May 3, 2006
About Loramyc: Loramyc (miconazole Lauriad(R)), a 50 mg Bioadhesive Buccal Tablet, has completed two Phase III clinical trials in Europe for treatment of ... - PharmaLive.com

Off-Label Drug Use  May 2, 2006
Many of the ophthalmic (eye) drugs are from human medicine, particularly ones such as miconazole, natamycin, and itraconazole used for treating fungal ... - TheHorse.com





BioAlliance Pharma Announces 2005 Financial Results  Mar 31, 2006
BioAlliance Pharma has developed a product called Loramyc(R) (miconazole Lauriad) for the treatment of oropharyngeal candidiasis. ... - Business Wire

Barrier Therapeutics to Present at CIBC World Markets Annual ...  Mar 29, 2006
The Company currently markets two pharmaceutical products in the United States, Vusion™ (0.25% miconazole nitrate, 15% zinc oxide, and 81.35% white petrolatum ... - Market Wire

Barrier Therapeutics Acquires the Canadian Distribution Rights For ...  Mar 15, 2006
In the US, Barrier markets Vusion ™ (0.25% miconazole nitrate, 15% zinc oxide and 81.35% white petrolatum) Ointment for the treatment of diaper dermatitis ... - PharmaLive.com

Mochida Health Care to Launch New Dandruff Shampoo  Mar 9, 2006
The new product, which contains miconazole nitrate as an active ingredient, inhibits the propagation of bacteria and prevents dandruff and itchy scalp. ... - Japan Corporate News



Basic Science Investigation  Feb 9, 2006
Cimetidine, diclofenac, and miconazole, known inhibitors of CYP450 2EI, were tested for the ability to inhibit defluorination of 18 F-FCWAY in rat liver ... - Journal of Nuclear Medicine

FDA Approves Vusion Ointment for the Treatment of Diaper ...  Feb 17, 2006
...products in the field of dermatology, today announced that the US Food and Drug Administration (FDA) has approved Vusion™ (0.25% miconazole nitrate, 15% zinc ... - PharmaLive.com,

5 Killer Ways To Treat Athlete’s Foot  Feb 20, 2006
...or drug store. Look for creams and ointments that contain clotrimazole or miconazole as their active ingredient. These are topical ... - DailyIndia.com,

Coffee in moderation relatively harmless  Feb 6, 2006
Miconazole suppositories or cream, clotrimazole suppositories or cream, Mycelex cream and oral Diflucan are a few examples of medicines. ... - Columbus Dispatch

BioAlliance Pharma Appoints Former GlaxoSmithKline Executive as ...  Jan 23, 2006
The Company's most advanced product, the Loramyc(R) (miconazole Lauriad(R)) 50 mg Bioadhesive Buccal Tablet, has completed two Phase III clinical trials in ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional